RETRACTED: HnRNP A1-mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395 (Retracted article. See vol. 42, 2023)

被引:15
|
作者
Sun, Guoliang [1 ,2 ]
Zhou, Hui [1 ,2 ]
Chen, Ke [1 ,2 ]
Zeng, Jin [1 ,2 ]
Zhang, Yangjun [1 ,2 ]
Yan, Libin [1 ,2 ]
Yao, Weimin [1 ,2 ]
Hu, Junhui [2 ,3 ]
Wang, Tao [4 ]
Xing, Jinchun [4 ]
Xiao, Kefeng [5 ]
Wu, Lily [3 ]
Ye, Zhangqun [1 ,2 ]
Xu, Hua [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan 430030, Peoples R China
[2] Hubei Inst Urol, Wuhan 430030, Peoples R China
[3] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Xiamen Univ, Dept Urol, Affiliated Hosp 1, Xiamen 361000, Peoples R China
[5] Peoples Hosp Shenzhen City, Dept Urol, Shenzhen 518000, Peoples R China
基金
中国国家自然科学基金;
关键词
ccRCC; CCDC50; Alternative splicing; HnRNP A1; ZNF395; GROWTH-FACTOR RECEPTOR; KAPPA-B; ACTIVATION; YMER; GENE; SUPPRESSION; LYMPHOMA; EGFR;
D O I
10.1186/s13046-020-01606-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Aberrant alternative splicing events play critical roles in carcinogenesis and progression of many cancers, while sparse studies regarding to alternative splicing are available for clear cell renal cell carcinoma (ccRCC). We identified that alternative splicing of coiled-coil domain containing 50 (CCDC50) was dysregulated in ccRCC, whereas the clinical significance of this splicing event and its splicing regulation mechanisms were still elusive. Methods Bioinformatic algorithm was utilized to identify significant exon skipping events in ccRCC via exon sequencing data from The Cancer Genome Atlas. Semi-quantitative real-time polymerase chain reaction and western blot were used to validate the aberrant expression of different transcripts in renal cancer tissues, cell lines and corresponding noncancerous controls. Short hairpin RNA targeting CCDC50 and overexpressing plasmids for each transcript were introduced into ccRCC cell lines, followed by a series of in vitro and in vivo functional experiments. Moreover, a panel of splicing factors were identified and their roles on splicing regulation of CCDC50 precursor mRNA (pre-mRNA) were studied. Furthermore, RNAseq data were analyzed to elucidate downstream molecules of CCDC50. Two-way analysis of variance and unpaired Student t test were used in statistical analysis. Results Pre-mRNA of CCDC50 generated two transcripts, full-length transcript (CCDC50-FL) and truncated transcript (CCDC50-S) with exon 6 skipped. CCDC50-S was overexpressed in ccRCC tissues and cell lines compared to noncancerous counterparts, but CCDC50-FL was only detected in noncancerous tissues and normal renal epithelial cells. Higher percent spliced-in index was associated with better survival in ccRCC patients. In vitro and in vivo functional experiments indicated that CCDC50-S transcript promoted the proliferation, migration, invasion and tumorigenesis of ccRCC, while CCDC50-FL exerted opposite tumor suppressive functions. Besides, we identified that heterogeneous nuclear ribonucleoprotein A1 (HnRNP A1) could promote the skipping of exon 6, which resulted in higher portion of CCDC50-S and oncogenic transformation. Moreover, zinc finger protein 395 (ZNF395) was identified as a downstream protein of CCDC50-S, and the interaction initiated oncogenic pathways which were involved in ccRCC progression. Conclusions Aberrant alternative splicing of CCDC50 is regulated by HnRNP A1 in ccRCC. This splicing event contributes to cancer progression through the downstream pathway involving ZNF395.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] RETRACTED ARTICLE: HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395
    Guoliang Sun
    Hui Zhou
    Ke Chen
    Jin Zeng
    Yangjun Zhang
    Libin Yan
    Weimin Yao
    Junhui Hu
    Tao Wang
    Jinchun Xing
    Kefeng Xiao
    Lily Wu
    Zhangqun Ye
    Hua Xu
    [J]. Journal of Experimental & Clinical Cancer Research, 39
  • [2] Retraction Note: HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395
    Guoliang Sun
    Hui Zhou
    Ke Chen
    Jin Zeng
    Yangjun Zhang
    Libin Yan
    Weimin Yao
    Junhui Hu
    Tao Wang
    Jinchun Xing
    Kefeng Xiao
    Lily Wu
    Zhangqun Ye
    Hua Xu
    [J]. Journal of Experimental & Clinical Cancer Research, 42
  • [3] RETRACTION: HnRNP A1-mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395 (vol 39, 116, 2020) (Retraction of Vol 39, Pg 116, 2020)
    Sun, Guoliang
    Zhou, Hui
    Chen, Ke
    Zeng, Jin
    Zhang, Yangjun
    Yan, Libin
    Yao, Weimin
    Hu, Junhui
    Wang, Tao
    Xing, Jinchun
    Xiao, Kefeng
    Wu, Lily
    Ye, Zhangqun
    Xu, Hua
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
  • [4] HNRNP A2/B1-MEDIATED ALTERNATIVE SPLICING OF CCDC50 CONTRIBUTE TO CANCER PROGRESSION OF CLEAR CELL RENAL CELL CARCINOMA
    Sun, Guoliang
    Zhou, Hui
    Yan, Libin
    [J]. JOURNAL OF UROLOGY, 2020, 203 : E1298 - E1298
  • [5] RETRACTED: KIF4A Promotes Clear Cell Renal Cell Carcinoma (ccRCC) Proliferation in vitro and in vivo (Retracted article. See vol. 16, pg. 309, 2023)
    Yang, Guang-Hua
    Ren, Zhi-Xing
    Yang, Xiong
    Zhang, Yan-Gang
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 2667 - 2676
  • [6] RETRACTED: Association between Mutation in SMARCAD1 and Basan Syndrome with Cutaneous Squamous Cell Carcinoma (Retracted article. See vol. 2023, 2023)
    Xiong, Ying
    Chen, Ting
    Yu, Jia
    Zhou, He
    Lu, Baozhen
    Chen, Lijie
    Sun, Liwei
    Wang, Can
    Li, Sujun
    Wu, Bo
    [J]. DISEASE MARKERS, 2022, 2022
  • [7] RETRACTED: Parecoxib inhibits esophageal squamous cell carcinoma progression via the PDK1-AKT pathway (Retracted article. See vol. 27, 2022)
    Huang, Han-Ming
    Huang, Xiao-Yu
    Wu, Shao-Ping
    Chen, Can-Keng
    He, Xin-Hua
    Zhang, Yong-Fa
    [J]. CELLULAR & MOLECULAR BIOLOGY LETTERS, 2022, 27 (01)
  • [8] RETRACTED: Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis (Retracted article. See vol. 49, 2023)
    Yoshiba, Sayaka
    Iwase, Masayasu
    Kurihara, Sayaka
    Uchida, Makiko
    Kurihara, Yuji
    Watanabe, Hitoshi
    Shintani, Satoru
    [J]. ONCOLOGY REPORTS, 2011, 25 (03) : 645 - 652
  • [9] RETRACTED: LncRNA DLEU1 accelerates the malignant progression of clear cell renal cell carcinoma via regulating miRNA-194-5p (Retracted article. See vol. 24, pg. 10920, 2020)
    He, G. -Z.
    Yu, S. -Y.
    Zhou, Q. -P.
    Chen, M. -L.
    Zhang, Y. -W.
    Zheng, Y.
    Zhang, Z. -B.
    Han, Z. -Y.
    Yu, J.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (24) : 10691 - 10698
  • [10] RETRACTED: Overexpression of SATB1 Is Associated with Biologic Behavior in Human Renal Cell Carcinoma (Retracted article. See vol. 19, 2024)
    Cheng, Chao
    Wan, Feng
    Liu, Lian
    Zeng, Fuqing
    Xing, Shi'an
    Wu, Xiaofei
    Chen, Xuepan
    Zhu, Zhaohui
    [J]. PLOS ONE, 2014, 9 (05):